Eli Lilly and Company
Anti-PD-L1-anti-TIM-3 bispecific antibodies
Last updated:
Abstract:
The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human TIM-3, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
Status:
Grant
Type:
Utility
Filling date:
12 Mar 2019
Issue date:
7 Jun 2022